CA2482512A1 - Improved viral purification methods - Google Patents

Improved viral purification methods Download PDF

Info

Publication number
CA2482512A1
CA2482512A1 CA002482512A CA2482512A CA2482512A1 CA 2482512 A1 CA2482512 A1 CA 2482512A1 CA 002482512 A CA002482512 A CA 002482512A CA 2482512 A CA2482512 A CA 2482512A CA 2482512 A1 CA2482512 A1 CA 2482512A1
Authority
CA
Canada
Prior art keywords
reovirus
virus
cells
culture
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002482512A
Other languages
French (fr)
Other versions
CA2482512C (en
Inventor
Matthew C. Coffey
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oncolytics Biotech Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=29406789&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2482512(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Individual filed Critical Individual
Publication of CA2482512A1 publication Critical patent/CA2482512A1/en
Application granted granted Critical
Publication of CA2482512C publication Critical patent/CA2482512C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/15—Reoviridae, e.g. calf diarrhea virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12051—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12211—Orthoreovirus, e.g. mammalian orthoreovirus
    • C12N2720/12222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12211—Orthoreovirus, e.g. mammalian orthoreovirus
    • C12N2720/12234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12211—Orthoreovirus, e.g. mammalian orthoreovirus
    • C12N2720/12251—Methods of production or purification of viral material

Abstract

The present invention is directed to an improved method of purifying virus, particularly reovirus. Infectious virus can be extracted from a cell culture with a detergent to produce high titers of virus, and the virus can then be purified by simple steps such as filtration and column chromatography. Viruses and compositions comprising the viruses prepared according to the present invention are also provided.

Claims (23)

1. A method of producing virus from a culture of cells, comprising the steps of:
(a) providing a culture of cells which has been infected by the virus;
(b) extracting the virus from the cells by adding a detergent to the culture and incubating for a period of time to result in a cell lysate;
(c) removing cell debris; and (d) collecting the virus.
2. The method of claim 1 wherein the cell debris is removed by filtration.
3. The method of claim 1 wherein the cell debris is removed by step-wise filtration comprising:
(1) filtering through a prefilter having a pore size of 5 µM or 8 µM, and (2) filtering after step (1) through a combination filter having pore sizes of µM and 0.8 µM.
4. The method of claim 1 further comprising treating the cell lysate with benzonase.
5. The method of claim 2 further comprising concentrating the filtrate.
6. The method of claim 5 wherein the filtrate is concentrated by diafiltration.
7. The method of claim 1 wherein the virus is a non-enveloped virus.
8. The method of claim 1 wherein the virus is a reovirus.
9. The method of claim 8 wherein the reovirus is a mammalian reovirus.
10. The method of claim 9 wherein the mammalian reovirus is a human reovirus.
11. The method of claim 10 wherein the human reovirus is a serotype 3 virus.
12. The method of claim 11 wherein the serotype 3 reovirus is the bearing strain.
13. The method of claim 1 wherein the reovirus is a recombinant reovirus.
14. The method of claim 1 wherein the cells are human embryo kidney 293 (HEK
293) cells.
15. The method of claim 14 wherein the HEK 293 cells are grown in suspension.
16. The method of claim 1 further comprising purifying the virus by anion exchange chromatography.
17. The method of claim 1 further comprising purifying the virus by a combination of ion exchange and size exclusion chromatography
18. A composition comprising the virus collected according to claim 1.
19. The composition of claim 18 which is suitable for clinical administration.
20. The composition of claim 19 further comprising a pharmaceutically acceptable excipient and/or carrier.
21. A method of producing infectious reovirus, comprising:
(a) providing a culture of HEK 293 cells which has been infected by reovirus;
(b) extracting the virus from the cells by adding Triton X-100 to the culture and incubating at about 25°C to about 37°C;
(c) treating the mixture from step (b) with benzonase;

(d) removing cell debris by filtration;
(e) concentrating the filtrate by ultrafiltration or diafiltration;
(f) purifying the reovirus by a combination of ion exchange and size exclusion chromatography; and (g) collecting the reovirus.
22. A composition comprising the reovirus prepared according to the method of claim 21.
23. The composition of claim 22 further comprising a pharmaceutically acceptable excipient and/or carrier.
CA2482512A 2002-04-30 2003-04-28 Improved viral purification methods Expired - Lifetime CA2482512C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US37727302P 2002-04-30 2002-04-30
US60/377,273 2002-04-30
US44317603P 2003-01-29 2003-01-29
US60/443,176 2003-01-29
PCT/CA2003/000624 WO2003093463A1 (en) 2002-04-30 2003-04-28 Improved viral purification methods

Publications (2)

Publication Number Publication Date
CA2482512A1 true CA2482512A1 (en) 2003-11-13
CA2482512C CA2482512C (en) 2011-09-20

Family

ID=29406789

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2482512A Expired - Lifetime CA2482512C (en) 2002-04-30 2003-04-28 Improved viral purification methods

Country Status (17)

Country Link
US (3) US7223585B2 (en)
EP (1) EP1501921B2 (en)
JP (1) JP2005523722A (en)
AR (1) AR039783A1 (en)
AT (1) ATE427990T1 (en)
AU (1) AU2003229159B2 (en)
BR (1) BR0309659A (en)
CA (1) CA2482512C (en)
DE (1) DE60327069D1 (en)
DK (1) DK1501921T4 (en)
ES (1) ES2323454T5 (en)
HK (1) HK1070670A1 (en)
IL (1) IL164551A (en)
MX (1) MXPA04010603A (en)
NZ (1) NZ535944A (en)
TW (1) TWI317378B (en)
WO (1) WO2003093463A1 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006042414A1 (en) * 2004-10-22 2006-04-27 Oncolytics Biotech Inc. Improved viral purification methods
US8685734B2 (en) 2002-04-30 2014-04-01 Oncolytics Biotech Inc. Viral purification methods

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2503774C (en) * 2003-06-20 2007-09-25 Microbix Biosystems Inc. Improvements in virus production
US8373381B2 (en) 2005-04-22 2013-02-12 GM Global Technology Operations LLC DC/DC-less coupling of matched batteries to fuel cells
US10668119B2 (en) 2005-08-01 2020-06-02 Virocure, Inc. Attenuated reovirus
US10260049B2 (en) 2005-08-01 2019-04-16 Virocure, Inc. Attenuated reovirus
JP5129805B2 (en) * 2006-04-20 2013-01-30 ワイス・エルエルシー Purification process for isolation of purified vesicular stomatitis virus from cell culture
US20080131955A1 (en) * 2006-11-30 2008-06-05 Canon U.S. Life Sciences, Inc. Method of Separating Target DNA from Mixed DNA
US10369171B2 (en) 2007-03-13 2019-08-06 Virocure, Inc. Attenuated reoviruses for selection of cell populations
AU2009296628B2 (en) * 2008-09-24 2015-01-15 Medimmune, Llc Methods for purification of viruses
JP2013523175A (en) 2010-04-14 2013-06-17 イーエムディー・ミリポア・コーポレーション Method for producing high-titer and high-purity virus stock and method for using the same
CN103347535B (en) 2010-12-02 2015-11-25 昂科利蒂克斯生物科技公司 Liquid virus preparation
AU2011336410B2 (en) 2010-12-02 2015-01-22 Oncolytics Biotech Inc. Lyophilized viral formulations
EA201391605A1 (en) * 2011-04-29 2014-02-28 Онколитикс Байотек Инк. METHODS OF CLEANING VIRUSES USING GELPRODUCTING CHROMATOGRAPHY
EP2970920B1 (en) * 2013-03-15 2018-04-25 The Children's Hospital of Philadelphia Scalable manufacturing process to produce recombinant lentiviral vectors in serum-free suspension cell culture system
FR3014901B1 (en) 2013-12-17 2017-06-09 Genethon PROCESS FOR PURIFYING ENHANCED VIRUSES OR VIRTORS
CN105900240A (en) * 2014-01-14 2016-08-24 皇家飞利浦有限公司 Organic light emitting diode
WO2016130569A1 (en) * 2015-02-09 2016-08-18 Mj Biologics, Inc. A composition comprising pedv antigens and methods for making and using the composition
EP3151866B1 (en) 2014-06-09 2023-03-08 Voyager Therapeutics, Inc. Chimeric capsids
MX2017005834A (en) 2014-11-05 2017-11-17 Voyager Therapeutics Inc Aadc polynucleotides for the treatment of parkinson's disease.
CN112410339A (en) 2014-11-14 2021-02-26 沃雅戈治疗公司 Regulatory polynucleotides
MX2017006216A (en) 2014-11-14 2018-08-29 Voyager Therapeutics Inc Compositions and methods of treating amyotrophic lateral sclerosis (als).
US11697825B2 (en) 2014-12-12 2023-07-11 Voyager Therapeutics, Inc. Compositions and methods for the production of scAAV
US20180230489A1 (en) 2015-10-28 2018-08-16 Voyager Therapeutics, Inc. Regulatable expression using adeno-associated virus (aav)
EP3448874A4 (en) 2016-04-29 2020-04-22 Voyager Therapeutics, Inc. Compositions for the treatment of disease
EP3448987A4 (en) 2016-04-29 2020-05-27 Voyager Therapeutics, Inc. Compositions for the treatment of disease
EP3458589A4 (en) 2016-05-18 2020-01-01 Voyager Therapeutics, Inc. Compositions and methods of treating huntington's disease
US10584337B2 (en) 2016-05-18 2020-03-10 Voyager Therapeutics, Inc. Modulatory polynucleotides
EP3506817A4 (en) 2016-08-30 2020-07-22 The Regents of The University of California Methods for biomedical targeting and delivery and devices and systems for practicing the same
WO2018204803A1 (en) 2017-05-05 2018-11-08 Voyager Therapeutics, Inc. Compositions and methods of treating huntington's disease
US11603542B2 (en) 2017-05-05 2023-03-14 Voyager Therapeutics, Inc. Compositions and methods of treating amyotrophic lateral sclerosis (ALS)
JOP20190269A1 (en) 2017-06-15 2019-11-20 Voyager Therapeutics Inc Aadc polynucleotides for the treatment of parkinson's disease
CA3070087A1 (en) 2017-07-17 2019-01-24 Voyager Therapeutics, Inc. Trajectory array guide system
US11512327B2 (en) 2017-08-03 2022-11-29 Voyager Therapeutics, Inc. Compositions and methods for delivery of AAV
EP3697908A1 (en) 2017-10-16 2020-08-26 Voyager Therapeutics, Inc. Treatment of amyotrophic lateral sclerosis (als)
US11434502B2 (en) 2017-10-16 2022-09-06 Voyager Therapeutics, Inc. Treatment of amyotrophic lateral sclerosis (ALS)
EP3762500A1 (en) 2018-03-06 2021-01-13 Voyager Therapeutics, Inc. Insect cell manufactured partial self-complementary aav genomes
WO2019222441A1 (en) 2018-05-16 2019-11-21 Voyager Therapeutics, Inc. Aav serotypes for brain specific payload delivery
WO2019222444A2 (en) 2018-05-16 2019-11-21 Voyager Therapeutics, Inc. Directed evolution
WO2020010042A1 (en) 2018-07-02 2020-01-09 Voyager Therapeutics, Inc. Treatment of amyotrophic lateral sclerosis and disorders associated with the spinal cord
SG11202100704PA (en) 2018-07-24 2021-02-25 Voyager Therapeutics Inc Systems and methods for producing gene therapy formulations
EP3861113A1 (en) 2018-10-04 2021-08-11 Voyager Therapeutics, Inc. Methods for measuring the titer and potency of viral vector particles
EP3911410A1 (en) 2019-01-18 2021-11-24 Voyager Therapeutics, Inc. Methods and systems for producing aav particles
WO2020223274A1 (en) 2019-04-29 2020-11-05 Voyager Therapeutics, Inc. SYSTEMS AND METHODS FOR PRODUCING BACULOVIRAL INFECTED INSECT CELLS (BIICs) IN BIOREACTORS
EP4010465A1 (en) 2019-08-09 2022-06-15 Voyager Therapeutics, Inc. Cell culture medium for use in producing gene therapy products in bioreactors
WO2021041485A1 (en) 2019-08-26 2021-03-04 Voyager Therapeutics, Inc. Controlled expression of viral proteins
US20230295656A1 (en) 2020-08-06 2023-09-21 Voyager Therapeutics, Inc. Cell culture medium for use in producing gene therapy products in bioreactors
EP4301768A2 (en) 2021-03-03 2024-01-10 Voyager Therapeutics, Inc. Controlled expression of viral proteins
WO2022187548A1 (en) 2021-03-03 2022-09-09 Voyager Therapeutics, Inc. Controlled expression of viral proteins
WO2024054983A1 (en) 2022-09-08 2024-03-14 Voyager Therapeutics, Inc. Controlled expression of viral proteins

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4721675A (en) 1982-02-01 1988-01-26 Abbott Laboratories Production of hepatitis A virus in vitro utilizing a persistently virus infected cell culture system
JPS6344532A (en) 1986-08-11 1988-02-25 Biseibutsu Kagaku Kenkyusho:Kk Vaccine for reovirus infection disease or swine
US5948441A (en) * 1988-03-07 1999-09-07 The Liposome Company, Inc. Method for size separation of particles
US5223409A (en) * 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5658779A (en) * 1992-03-20 1997-08-19 Ligochem, Inc. Method of adsorbing viruses from fluid compositions
DZ1706A1 (en) 1992-08-07 2002-02-17 Merck & Co Inc Hepatitis A vaccine.
FR2696748B1 (en) * 1992-10-14 1994-12-30 Pasteur Merieux Serums Vacc Process for the preparation of hepatitis A antigens and vaccines (HAV).
US5614413A (en) * 1993-07-01 1997-03-25 The Uab Research Foundation Encapsidated recombinant poliovirus nucleic acid and methods of making and using same
US6686200B1 (en) * 1993-08-31 2004-02-03 Uab Research Foundation Methods and compositions for the large scale production of recombinant adeno-associated virus
HRP950097A2 (en) 1994-03-08 1997-06-30 Merck & Co Inc Hepatitis a virus culture process
RU2206608C2 (en) 1994-05-16 2003-06-20 Мерк Энд Ко., Инк. Papilloma viral vaccines
US6146873A (en) 1994-11-10 2000-11-14 Baxter Aktiengesellschaft Production of orthomyxoviruses in monkey kidney cells using protein-free media
AR004464A1 (en) 1994-11-14 1998-12-16 Merck Sharp & Dohme A METHOD FOR PRODUCING A PAPILOMAVIRUS CAPSIDE PROTEIN
WO1997008298A1 (en) * 1995-08-30 1997-03-06 Genzyme Corporation Chromatographic purification of adenovirus and aav
ATE348155T1 (en) * 1996-11-20 2007-01-15 Introgen Therapeutics Inc AN IMPROVED METHOD FOR PRODUCTION AND PURIFICATION OF ADENOVIRAL VECTORS
DE69737364T2 (en) 1996-12-13 2007-11-29 Schering Corp. METHODS FOR VIRUS CLEANING
TW570803B (en) 1997-04-09 2004-01-11 Duphar Int Res Influenza vaccine
US6214333B1 (en) 1997-07-08 2001-04-10 Texas Heart Institute Vasoprotective recombinant adenovirus vector containing a human TFPI gene
US6110461A (en) 1997-08-13 2000-08-29 Oncolytics Biotech Inc. Reovirus for the treatment of neoplasia
GB9804632D0 (en) 1998-03-05 1998-04-29 Cantab Pharma Res Virus preparations and methods
CA2410948C (en) 2000-05-31 2012-07-17 Chiron Corporation Method for the purification of alphavirus replicon particles
TWI289158B (en) * 2000-08-10 2007-11-01 Oncolytics Biotech Inc Method of producing infectious reovirus
DK2253701T3 (en) 2001-03-16 2014-10-20 Oncolytics Biotech Inc Method of extracting a virus from a cell culture
CA2482512C (en) 2002-04-30 2011-09-20 Oncolytics Biotech Inc. Improved viral purification methods
US7901921B2 (en) * 2004-10-22 2011-03-08 Oncolytics Biotech Inc. Viral purification methods

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8685734B2 (en) 2002-04-30 2014-04-01 Oncolytics Biotech Inc. Viral purification methods
US10167452B2 (en) 2002-04-30 2019-01-01 Oncolytics Biotech Inc. Viral purification methods
WO2006042414A1 (en) * 2004-10-22 2006-04-27 Oncolytics Biotech Inc. Improved viral purification methods
AU2005297372B2 (en) * 2004-10-22 2010-08-26 Oncolytics Biotech Inc. Improved viral purification methods
US7901921B2 (en) 2004-10-22 2011-03-08 Oncolytics Biotech Inc. Viral purification methods

Also Published As

Publication number Publication date
US20140178969A1 (en) 2014-06-26
IL164551A0 (en) 2005-12-18
HK1070670A1 (en) 2005-06-24
EP1501921B1 (en) 2009-04-08
AR039783A1 (en) 2005-03-02
WO2003093463A1 (en) 2003-11-13
US20070269856A1 (en) 2007-11-22
MXPA04010603A (en) 2004-12-13
AU2003229159B2 (en) 2008-02-21
DE60327069D1 (en) 2009-05-20
TW200401829A (en) 2004-02-01
DK1501921T4 (en) 2012-10-08
US10167452B2 (en) 2019-01-01
IL164551A (en) 2010-05-17
NZ535944A (en) 2007-11-30
EP1501921A1 (en) 2005-02-02
JP2005523722A (en) 2005-08-11
US20040005693A1 (en) 2004-01-08
EP1501921B2 (en) 2012-07-25
US7223585B2 (en) 2007-05-29
BR0309659A (en) 2005-02-22
CA2482512C (en) 2011-09-20
US8685734B2 (en) 2014-04-01
TWI317378B (en) 2009-11-21
ES2323454T5 (en) 2012-11-14
ES2323454T3 (en) 2009-07-16
ATE427990T1 (en) 2009-04-15
DK1501921T3 (en) 2009-06-22
AU2003229159A1 (en) 2003-11-17

Similar Documents

Publication Publication Date Title
CA2482512A1 (en) Improved viral purification methods
CA2584142A1 (en) Improved viral purification methods
JP5129805B2 (en) Purification process for isolation of purified vesicular stomatitis virus from cell culture
JP2015521628A5 (en)
JP2009034115A5 (en)
US6149917A (en) Industrial production process for a vaccine against Japanese encephalitis virus and vaccine produced
JP2012503489A5 (en)
CA2879815A1 (en) Purification of virus like particles
JP2013236633A5 (en)
RU2002124857A (en) The method of obtaining IgG
MXPA06008435A (en) Process for the manufacture of virus safe immunoglobulin.
JP2008518632A5 (en)
EA028623B1 (en) Method for the purification of adenovirus particles
CA2859916C (en) Purification of herpes virus
CN106574252B (en) Method for purifying poliovirus from cell culture
EP0480949B2 (en) Production of viral vaccine
WO2014015816A1 (en) Method for removing host dna from vaccine
US6245549B1 (en) Production of virus and purification of viral envelope proteins for vaccine use
CN109134622A (en) The multistep continuous Integration purification process of foot-and-mouth disease virus antigen
RU2493872C1 (en) Method for influenza virus purification
CN103642760A (en) Method for preparing Coxsackie A16 virus complete solid particles
CN109337875B (en) Method for purifying lentivirus
NISHIMURA et al. Concentration and purification of eel virus, EVE
US20180273909A1 (en) Purification of respiratory syncytial virus
SU520778A1 (en) Method of filtration of solutions and suspensions of microorganisms and/or proteins

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry

Effective date: 20230428